Fanconi syndrome after a single exposure to intravenous zoledronic acid
Author(s)
Deb, Rita
Elboghday, Muhammad
Shrestha, Alvin
Type
Journal Article
Abstract
Bisphosphonates are commonly used to reduce fracture risk in patients with osteoporosis, in those with malignant metastatic bone disease and for treatment of malignant hypercalcaemia. We present the case of a woman in her 80s admitted with recurrent falls who developed Fanconi syndrome after a single dose of intravenous Zoledronic acid despite normal renal function. In this report, we review the literature exploring nephrotoxicity secondary to Zoledronic acid use, recognizing that there are other reported cases of Fanconi syndrome; however, all in patients with malignancy rather than for osteoporosis. We also present one of the first cases of Fanconi syndrome after just a single exposure to Zoledronic acid in a patient who had normal preceding renal function. This highlights the need to be aware of the possibility of significant nephrotoxicity after a single exposure to Zoledronic acid even without the recognized risk factors of chronic or acute kidney disease.
Date Issued
2026-02-01
Date Acceptance
2026-01-06
Citation
Clinical Case Reports, 2026, 14 (2)
ISSN
2050-0904
Publisher
Wiley
Journal / Book Title
Clinical Case Reports
Volume
14
Issue
2
Copyright Statement
© 2026 The Author(s). Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Identifier
10.1002/ccr3.71868
Subjects
endocrinology and metabolic disorders
general medicine
geriatrics
nephrology
pharmacology and pharmacy
Publication Status
Published
Article Number
e71868
Date Publish Online
2026-02-06